Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2017466 | 1.00 | SLC1A2 (0.34) | SLC1A2SLC1A1HSD11B1APLNRMEN1 | |
| SCHEMBL17110217 | 0.84 | AKR1B10 (0.36) | MEN1KMT2A | |
| SCHEMBL2505350 | 0.79 | ATM (0.37) | KMT2AHTT | |
| SCHEMBL2013946 | 0.79 | ATM (0.37) | KMT2AHTT | |
| SCHEMBL1536024 | 0.79 | MEN1 (0.35) | SLC1A2SLC1A1HSD11B1APLNRMEN1 | |
| SCHEMBL17048890 | 0.75 | PSEN1 (0.39) | MEN1KMT2AHTT | |
| SCHEMBL17118118 | 0.75 | PSEN1 (0.39) | MEN1KMT2AHTT | |
| SCHEMBL19759347 | 0.75 | MAPK1 (0.39) | — | |
| SCHEMBL1642593 | 0.74 | CYP3A4 (0.41) | MEN1KMT2A | |
| SCHEMBL16612692 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2707357-B1 | PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-01-18 | — | — | EP | disclosed |
| EP-2513098-B1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9120785-B2 | Pyridyl aminopyridines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | ALTMAN MICHAEL D (US) | 2014-08-28 | — | — | US | disclosed |
| US-8759366-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140100250-A1 | PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-04-10 | — | — | US | disclosed |
| US-8551984-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-11-01 | — | — | US | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
| WO-2011075515-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | SLC1A2 3388/4885SLC1A1 3444/4885HSD11B1 2589/4885 |
| US-20140100250-A1 | PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS | SYK, BTK, LCK | SLC1A2 4277/4885SLC1A1 4016/4885HSD11B1 3432/4885 |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | SYK, BTK, LCK | SLC1A2 3388/4885SLC1A1 3444/4885HSD11B1 2589/4885 |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | SLC1A2 3388/4885SLC1A1 3444/4885HSD11B1 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.